BASEER SYED

Allopathic & Osteopathic Physicians|Internal Medicine FALLS CHURCH, VA NPI 1124524616

General Payments — all program years on this page

$979.52

  • Category: General Payments
  • Program years: PY2022–2024
  • Record count: 40
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $481.97 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $481.9719

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2022 $94.453
2023 $403.1018
2024 $481.9719

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1087309065 Novartis Pharmaceuticals Corporation $66.68 07/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097608518 Novo Nordisk Inc $17.29 03/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104214817 AstraZeneca Pharmaceuticals LP $31.16 10/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104329326 AstraZeneca Pharmaceuticals LP $18.09 08/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104538070 AstraZeneca Pharmaceuticals LP $17.24 11/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104618568 AstraZeneca Pharmaceuticals LP $23.90 04/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105652502 AstraZeneca Pharmaceuticals LP $1.52 11/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105652734 AstraZeneca Pharmaceuticals LP $17.72 06/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105840569 AstraZeneca Pharmaceuticals LP $28.54 04/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1113921044 Paratek Pharmaceuticals, Inc. $13.46 04/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1113921046 Paratek Pharmaceuticals, Inc. $18.03 08/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137914645 Electromed, Inc. $19.81 06/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1138829886 Edwards Lifesciences Corporation $17.65 03/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1145656477 Neurelis, Inc. $14.32 11/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153411869 Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.14 10/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153412781 Salix Pharmaceuticals, a division of Bausch Health US, LLC $23.49 09/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153497552 Salix Pharmaceuticals, a division of Bausch Health US, LLC $44.90 05/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153599577 Salix Pharmaceuticals, a division of Bausch Health US, LLC $41.63 06/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153713856 Salix Pharmaceuticals, a division of Bausch Health US, LLC $42.40 06/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.